Genetic Technology Alert. High-Priced Hepatitis C Drug Results in Development of Generic Products; FDA-Approved Rapid Antigen Test for Ebola; Focused Antiviral Clinical Programs for Infectious Diseases

Genetic Technology Alert. High-Priced Hepatitis C Drug Results in Development of Generic Products; FDA-Approved Rapid Antigen Test for Ebola; Focused Antiviral Clinical Programs for Infectious Diseases

RELEASE DATE
24-Jul-2015
REGION
Global
Research Code: D757-00-05-00-00
SKU: HC02737-GL-TA_19631

$250.00

Special Price $187.50 save 25 %

In stock
SKU
HC02737-GL-TA_19631

$250.00

$187.50 save 25 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

This issue profiles a high-priced hepatitis c drug that results in development of generic products, a rapid antigen test for Ebola, and focused antiviral clinical programs for infectious diseases.

Table of Contents

In This Issue

  • 1. HIGH-PRICED HEPATITIS C DRUG RESULTS IN DEVELOPMENT OF GENERIC PRODUCTS
  • 2. FOCUSED ANTIVIRAL CLINICAL PROGRAMS FOR INFECTIOUS DISEASES
  • 3. FDA-APPROVED RAPID ANTIGEN TEST FOR EBOLA
  • 4. KEY PATENTS ACROSS THERAPEUTICS FOR INFECTIOUS DISEASES
  • 5. TECHVISION 2015
This issue profiles a high-priced hepatitis c drug that results in development of generic products, a rapid antigen test for Ebola, and focused antiviral clinical programs for infectious diseases.
More Information
No Index No
Podcast No
Industries Healthcare
WIP Number D757-00-05-00-00
Is Prebook No
Ti Codes D758